BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
SNCA
,
T cell differentiation
,
Diabetes mellitus
,
Pancreas
,
Hematopoietic cell
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
kras protein, human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Colorectal cancer HKE3 cells expressing KRAS wildtype or G13D mutation and treated with TGFA
Lung cancer A549 cells treated with TGF-beta3
Lung cancer A549 cells (KRAS mutant) after BI-2536 and fasudil combination treatment
Colorectal cancer HCT-15 cells treated with MEK/TNKS inhibitors GDC-0973 or G007-LK respectively
Mammary gland MCF10A cells overexpressing mutant or wildtype KRas
Explore Curated Studies Results
Literature
Most Relevant Literature
Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency.
Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical ther…
A non-covalent inhibitor with pan-KRAS potential.
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.
RAS at 40: Update from the RAS Initiative.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With …
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ